TY - JOUR
T1 - Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification
T2 - Retrospective and validation phase
AU - Di Filippo, Franco
AU - Di Filippo, Simona
AU - Ferrari, Anna Maria
AU - Antonetti, Raffaele
AU - Battaglia, Alessandro
AU - Becherini, Francesca
AU - Bernet, Laia
AU - Boldorini, Renzo
AU - Bouteille, Catherine
AU - Buglioni, Simonetta
AU - Burelli, Paolo
AU - Cano, Rafael
AU - Canzonieri, Vincenzo
AU - Chiodera, Pierluigi
AU - Cirilli, Alfredo
AU - Coppola, Luigi
AU - Drago, Stefano
AU - Di Tommaso, Luca
AU - Fenaroli, Privato
AU - Franchini, Roberto
AU - Gianatti, Andrea
AU - Giannarelli, Diana
AU - Giardina, Carmela
AU - Godey, Florence
AU - Grassi, Massimo M.
AU - Grassi, Giuseppe B.
AU - Laws, Siobhan
AU - Massarut, Samuele
AU - Naccarato, Giuseppe
AU - Natalicchio, Maria Iole
AU - Orefice, Sergio
AU - Palmieri, Fabrizio
AU - Perin, Tiziana
AU - Roncella, Manuela
AU - Roncalli, Massimo G.
AU - Rulli, Antonio
AU - Sidoni, Angelo
AU - Tinterri, Corrado
AU - Truglia, Maria C.
AU - Sperduti, Isabella
N1 - Publisher Copyright:
© 2016 The Author(s).
PY - 2016/12/8
Y1 - 2016/12/8
N2 - Background: Tumor-positive sentinel lymph node (SLN) biopsy results in a risk of non sentinel node metastases in micro- and macro-metastases ranging from 20 to 50%, respectively. Therefore, most patients underwent unnecessary axillary lymph node dissections. We have previously developed a mathematical model for predicting patient-specific risk of non sentinel node (NSN) metastases based on 2460 patients. The study reports the results of the validation phase where a total of 1945 patients were enrolled, aimed at identifying a tool that gives the possibility to the surgeon to choose intraoperatively whether to perform or not axillary lymph node dissection (ALND). Methods: The following parameters were recorded: Clinical: hospital, age, medical record number; Bio pathological: Tumor (T) size stratified in quartiles, grading (G), histologic type, lymphatic/vascular invasion (LVI), ER-PR status, Ki 67, molecular classification (Luminal A, Luminal B, HER-2 Like, Triple negative); Sentinel and non-sentinel node related: Number of NSNs removed, number of positive NSNs, cytokeratin 19 (CK19) mRNA copy number of positive sentinel nodes stratified in quartiles. A total of 1945 patients were included in the database. All patient data were provided by the authors of this paper. Results: The discrimination of the model quantified with the area under the receiver operating characteristics (ROC) curve (AUC), was 0.65 and 0.71 in the validation and retrospective phase, respectively. The calibration determines the distance between predicted outcome and actual outcome. The mean difference between predicted/observed was 2.3 and 6.3% in the retrospective and in the validation phase, respectively. The two values are quite similar and as a result we can conclude that the nomogram effectiveness was validated. Moreover, the ROC curve identified in the risk category of 31% of positive NSNs, the best compromise between false negative and positive rates i.e. when ALND is unnecessary (<31%) or recommended (>31%). Conclusions: The results of the study confirm that OSNA nomogram may help surgeons make an intraoperative decision on whether to perform ALND or not in case of positive sentinel nodes, and the patient to accept this decision based on a reliable estimation on the true percentage of NSN involvement. The use of this nomogram achieves two main gools: 1) the choice of the right treatment during the operation, 2) to avoid for the patient a second surgery procedure.
AB - Background: Tumor-positive sentinel lymph node (SLN) biopsy results in a risk of non sentinel node metastases in micro- and macro-metastases ranging from 20 to 50%, respectively. Therefore, most patients underwent unnecessary axillary lymph node dissections. We have previously developed a mathematical model for predicting patient-specific risk of non sentinel node (NSN) metastases based on 2460 patients. The study reports the results of the validation phase where a total of 1945 patients were enrolled, aimed at identifying a tool that gives the possibility to the surgeon to choose intraoperatively whether to perform or not axillary lymph node dissection (ALND). Methods: The following parameters were recorded: Clinical: hospital, age, medical record number; Bio pathological: Tumor (T) size stratified in quartiles, grading (G), histologic type, lymphatic/vascular invasion (LVI), ER-PR status, Ki 67, molecular classification (Luminal A, Luminal B, HER-2 Like, Triple negative); Sentinel and non-sentinel node related: Number of NSNs removed, number of positive NSNs, cytokeratin 19 (CK19) mRNA copy number of positive sentinel nodes stratified in quartiles. A total of 1945 patients were included in the database. All patient data were provided by the authors of this paper. Results: The discrimination of the model quantified with the area under the receiver operating characteristics (ROC) curve (AUC), was 0.65 and 0.71 in the validation and retrospective phase, respectively. The calibration determines the distance between predicted outcome and actual outcome. The mean difference between predicted/observed was 2.3 and 6.3% in the retrospective and in the validation phase, respectively. The two values are quite similar and as a result we can conclude that the nomogram effectiveness was validated. Moreover, the ROC curve identified in the risk category of 31% of positive NSNs, the best compromise between false negative and positive rates i.e. when ALND is unnecessary (<31%) or recommended (>31%). Conclusions: The results of the study confirm that OSNA nomogram may help surgeons make an intraoperative decision on whether to perform ALND or not in case of positive sentinel nodes, and the patient to accept this decision based on a reliable estimation on the true percentage of NSN involvement. The use of this nomogram achieves two main gools: 1) the choice of the right treatment during the operation, 2) to avoid for the patient a second surgery procedure.
KW - CK19 mRNA number copies
KW - Nomogram
KW - Non Sentinel Node status
KW - OSNA method
UR - http://www.scopus.com/inward/record.url?scp=85008477709&partnerID=8YFLogxK
U2 - 10.1186/s13046-016-0460-6
DO - 10.1186/s13046-016-0460-6
M3 - Article
SN - 0392-9078
VL - 35
JO - Journal of Experimental and Clinical Cancer Research
JF - Journal of Experimental and Clinical Cancer Research
IS - 1
M1 - 193
ER -